Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer.
CONCLUSION: FOLFIRINOX is an option for the first-line treatment of patients with pancreatic cancer and good performance status.
PMID: 33315355 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | General Medicine | Pancreas | Pancreatic Cancer | Study | Turkey Health